Evidence map›Paper›PMID 33534631›Full record

ReviewDiabetes technology & therapeutics2021

Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring.

Melanie A Jackson, Andrew Ahmann, Viral N Shah

3 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes technology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05431296 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes

TypeinterventionalSponsorImperial College LondonRan2023 to 2025Enrolled160ConditionsType 2 Diabetes, Acute Myocardial Infarction, Acute Myocardial Infarction With ST Elevation, Diabetes ComplicationsArmsDexcom ONE Continuous Glucose Monitoring System
NCT06614127 active not recruitingnot on this mapstarted 2024, after this paper: background citation

Continuous Intraoperative Glucose Monitoring: A Pilot Study

TypeobservationalSponsorLoma Linda UniversityRan2024 to 2026Enrolled45ConditionsAnesthesiaArmsDexcom G7® sensor placed in upper arm and positioned over deltoid, Dexcom G7® sensor placed in lateral thigh
NCT06864546 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients With Type 2 Diabetes

TypeinterventionalSponsorEnea ParimbelliRan2025 to 2026Enrolled20ConditionsType 2 Diabetes Mellitus, Non Insulin DependentArmsPhysical activity intervention
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Melanie A JacksonDivision of Endocrinology, Diabetes, and Clinical Nutrition; Oregon Health and Science University, Portland, Oregon, USA.
Andrew AhmannHarold Schnitzer Diabetes Health Center, Oregon Health and Science University, Portland, Oregon, USA.
Viral N ShahBarbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Oregon Health & Science University · USUniversity of Colorado Anschutz Medical Campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of continuous glucose monitoring (CGM) in type 1 diabetes (T1D) is well established in improving glycemic control and reducing hypoglycemia. Type 2 diabetes (T2D) is more prevalent than T1D and management of T2D is more heterogeneous, requiring treatment ranging from lifestyle modification to oral medications to intensive insulin therapy. Recent randomized controlled trials in intensively insulin-treated T2D demonstrated the efficacy and safety of real-time CGM (rtCGM) in reducing glycated hemoglobin without increasing hypoglycemia. Although evidence is limited, early studies have indicated a role for rtCGM in selected patients with non-insulin requiring T2D to improve glycemic control and/or reduce hypoglycemia. Based on literature review, we summarized current data on the use of rtCGM in T2D management and provided future research direction to generate more evidence on the utility of CGM in this population.

Indexed as

Blood Glucose Self-MonitoringDiabetes Mellitus, Type 2Blood GlucoseGlycated HemoglobinHumansHypoglycemic AgentsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsContinuous glucose monitorGlucose monitoringGlycemic controlHbA1cType 2 diabetes

Identifiers

PMID33534631
PMCPMC7957379
OpenAlexW3126557659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.